Similar articles

• Use of an angiotensin II antagonist (saralasin) in the recognition of "angiotensinogenic" hypertension;

  Streeten DH, Anderson GH, Freiberg JM, Dalakos TG. Streeten DH, et al. N Engl J Med. 1975 Mar 27;292(13):657-62. doi: 10.1056/NEJM197503272921301. N Engl J Med. 1975. PMID: 235090
• [Exchange sodium and angiotensin II in the blood in essential arterial hypertension].

  Deutsch G, Cristodorescu R, Gavrilescu S, Berger E, Drugărin D. Deutsch G, et al. Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna. 1977 Mar-Apr;29(2):113-9. Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna. 1977. PMID: 17902 Romanian. No abstract available.
• Letter: Use and toxicity of nitroprusside.

  [No authors listed] [No authors listed] N Engl J Med. 1975 May 15;292(20):1081-2. doi: 10.1056/NEJM197505152922020. N Engl J Med. 1975. PMID: 235741 No abstract available.
• [Pharmacologic functional examination in arterial hypertension].

  Stumpe KO, Kolloch R, Overlack A. Stumpe KO, et al. Internist (Berl). 1977 Nov;18(11):594-600. Internist (Berl). 1977. PMID: 23361 Review. German. No abstract available.
• [Angiotensin II analogue and essential hypertension].

  Kono T, Ikeda F, Oseko F, Imura H, Shimbo S, Endo J. Kono T, et al. Nihon Rinsho. 1979 Oct;37(10):3503-10. Nihon Rinsho. 1979. PMID: 392137 Review. Japanese. No abstract available.